Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
Titel:
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
Auteur:
Fu, S. Hou, M.M. Naing, A. Janku, F. Hess, K. Zinner, R. Subbiah, V. Hong, D. Wheler, J. Piha-Paul, S. Tsimberidou, A. Karp, D. Araujo, D. Kee, B. Hwu, P. Wolff, R. Kurzrock, R. Meric-Bernstam, F.